Press Release

PhRMA Applauds the Release of the IPEC Strategic Plan

PhRMA April 30, 2013

Washington, D.C. (June 22, 2010) — Pharmaceutical Research and Manufacturers of America President and CEO, Billy Tauzin issued the following statement today on the release of the Joint Strategic Plan from the Intellectual Property Enforcement Coordinator (IPEC) Victoria Espinel:

“While intellectual property infringement threatens the ideas and innovations that are the lifeblood of pharmaceutical companies and in turn our industry’s important stake in the U.S. economy, it also presents a very real public health and safety danger to patients world-wide.

“We are therefore very pleased that the report from the IPEC recognizes that battling intellectual property infringement is so essential for our members. Only through effective IP enforcement can the United States achieve President Obama’s goal of doubling exports over the next five years, bolster the U.S. comparative advantage in ideas, and protect U.S. and global consumers and patients.

“Among other things, we applaud the Plan’s establishment of a Counterfeit Pharmaceutical Interagency Committee, its focus on robust enforcement of IP rights worldwide, and its goal of enhancing US advocacy on IP issues in multiple international forums.

“PhRMA recognizes the importance of protecting America’s patients against the threat of counterfeit drug products. We are reviewing the Plan’s specific recommendations designed to strengthen the prescription drug supply chain, and look forward to ongoing dialogue with Government stakeholders and others on these and other mechanisms that could help reduce and eliminate the presence of counterfeit drugs worldwide.”

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $50.3 billion in 2008 in discovering and developing new medicines. Industry-wide research and investment reached a record $65.2 billion in 2008.

PhRMA Internet Address:

For information on stories of hope and survival, visit:

PhRMA en Español:

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For more information on public health emergencies, visit:

For information on the danger of imported drugs, visit: